

MEDICAL USE OF CANNABIS FOR GLAUCOMA

October 2018

Paul Rafuse MD, PhD, FRCSC¹; Yvonne M Buys MD, FRCSC²

¹Department of Ophthalmology and Visual Sciences, Dalhousie University;

²Department of Ophthalmology and Vision Sciences, University of Toronto

Summary

The clinical utility of cannabis (sometimes referred to as marijuana or marihuana) for the treatment of glaucoma is limited by the inability to separate the potential clinical action from the undesirable neuropsychological and behavioural effects. The Canadian Ophthalmological Society does not support the medical use of cannabis for the treatment of glaucoma due to the short duration of action, the incidence of undesirable psychotropic and other systemic side effects and the absence of scientific evidence showing a beneficial effect on the course of the disease. This is in contrast to other more effective and less harmful medical, laser and surgical modalities for the treatment of glaucoma.

Full policy statement

The plant *Cannabis sativa* has long been recognized to have medicinal properties.¹ Over 400 compounds have been isolated but the two most active, Δ 9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have unique actions and potential therapeutic applications.² THC, first isolated in 1964,³ is responsible for the well known psychotropic effects when the dried plant or resin is smoked or ingested orally. THC is also responsible for appetite stimulation and control of nausea and vomiting. CBD may lessen muscle spasms and chronic pain.

In addition to its psychotropic effects, smoked THC was first noted to lower intraocular pressure (IOP) in 1971.⁴ Since then, other studies have confirmed the IOP lowering effect of THC by various modes of administration including inhalational,^{4,5} oral,⁶ intravenous,⁷ sublingual,⁸ and topical.⁹ Although topical application might seem to be an optimal route of administration, ocular penetration has been poor due to the high lipophilicity and low aqueous solubility of the cannabinoid extracts. Topical preparations have also been noted to cause local irritation and corneal injury. In addition, some studies have failed to find a hypotensive effect of topical THC.^{10,11} The oral route has also been limited by variable absorption.⁶ The mechanism of IOP reduction is not well understood.¹²⁻¹⁴ The maximum hypotensive effect occurs between 60-90 minutes and the duration of action of is brief at only 3-4 hours.^{4,15}

The main problems with inhaling the smoke of burning cannabis leaves and resin are the side effects which acutely include psychotropic effects (euphoria, dysphoria, decreased short-term memory, cognitive impairment, time distortion, decreased co-ordination, sleepiness),^{4,5} tachycardia, palpitations, systemic hypotension⁸ and conjunctival hyperaemia. The long-term effects of smoking cannabis include emphysema and possible lung cancer.¹⁶ There are also concerns about the potential addictive properties and the development of tolerance.¹⁷ The clinical utility of cannabis for the treatment of glaucoma is limited by the inability to separate the potential clinical action from the undesirable neuropsychological and behavioural effects.

The legalization of cannabis for recreational use in Canada, as well as its government regulated production, sale and distribution, may have other impacts. In jurisdictions where laws have relaxed restrictions on access, some societal costs have been noted to increase. Motor vehicle accidents attributable to the use of cannabis rose by a factor of 2 following legalization in Colorado¹⁸ and emergency room visits for injuries¹⁹, psychiatric and other medical issues have been noted to be higher in users, as opposed to non-users, of cannabis.²⁰

The Canadian Ophthalmological Society does not support the medical use of cannabis for the treatment of glaucoma due to the short duration of action, the incidence of undesirable psychotropic and other systemic side effects and the absence of scientific evidence showing a beneficial effect on the course of the disease. This is in contrast to other more effective and less harmful medical, laser and surgical modalities for the treatment of glaucoma.

References

1. Zias J, Stark H, Sellman J, et al. Early medical use of cannabis. *Nature* 1993;363:215.
2. Lieberman MF. Editorial: "Recreational" Marijuana. *Am J Ophthalmol* 2017;117:xv.
3. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of the active constituent of hashish. *J Am Chem Soc* 1964;86:1646-7.
4. Hepler RS, Frank IR. Marijuana smoking and intraocular pressure. *JAMA* 1971;217:1392.
5. Merritt JC, Crawford WJ, Alexander PC, Anduze AL, Gelbart SS. Effect of marijuana on intraocular and blood pressure in glaucoma. *Ophthalmology* 1980;87:222-8.
6. Merritt JC, McKinnon S, Armstrong JR, Hatem G, Reid LA. Oral delta 9-tetrahydrocannabinol in heterogeneous glaucomas. *Ann Ophthalmol* 1980;12:947-50.
7. Purnell WD, Gregg JM. Delta(9)-tetrahydrocannabinol, euphoria and intraocular pressure in man. *Ann Ophthalmol* 1975;7:921-3.
8. Tomida I, Azuara-Blanco A, House H, Fling M, Pertwee RG, Robson PJ. Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. *J Glaucoma* 2006;15:349-53.
9. Merritt JC, Olsen JL, Armstrong JR, McKinnon SM. Topical delta 9-tetrahydrocannabinol in hypertensive glaucomas. *J Pharm Pharmacol* 1981;33:40-1.
10. Green K, Roth M. Ocular effects of topical administration of delta 9-tetrahydrocannabinol in man. *Arch Ophthalmol* 1982;100:265-7.
11. Jay WM, Green K. Multiple-drop study of topically applied 1% delta 9-tetrahydrocannabinol in human eyes. *Arch Ophthalmol* 1983;101:591-3.
12. Green K, Podos SM. Antagonism of arachidonic acid-induced ocular effects by D1-tetrahydrocannabinol. *Invest Ophthalmol*. 1974;13:422-429.
13. Porcella A, Casellas P, Gessa GL, et al. Cannabinoid receptor CB1 mRNA is highly expressed in the rat ciliary body: implications for the antiglaucoma properties of marijuana. *Brain Res Mol Brain Res* 1998;58:240-245.
14. Zhan GL, Camras CB, Palmber PF, Toris CB. Effects of marijuana on aqueous humor dynamics in a glaucoma patient. *J Glaucoma* 2005;14:175-7.
15. Brown B, Adams AJ, Haegerstrom-Portnoy G, et al. Pupil size after use of marijuana and alcohol. *Am J Ophthalmol* 1977;83:350-4.
16. Hashibe M, Ford DE, Zhang ZF. Marijuana smoking and head and neck cancer. *J*

- Clin Pharmacol* 2002;42(Suppl):103–7.
17. Flom MC, Adams AJ, Jones RT. Marijuana smoking and reduced pressure in human eyes: drug action or epiphenomenon? *Invest Ophthalmol* 1975;14:52–5.
 18. Salomonsen-Sautel S, Min SJ, Sakai JT, Thurstone C, Hopfer C. Trends in fatal motor vehicle crashes before and after marijuana commercialization in Colorado. *Drug Alcohol Depend* 2014;140:137.
 19. Choi NG, Marti CN, DiNitto DM, Choi BY. Older adults' marijuana use, injuries, and emergency department visits. *Am J Drug Alcohol Abuse* 2018;44:215.
 20. Campbell CI, Baborik AL, Kline-Simon AH, Satre DD. The role of marijuana use disorder in predicting emergency department and patient encounters: A retrospective cohort study. *Drug Alcohol Depend* 2017;178:170.